Physical Medicine & Rehabilitation Doctors in Cary, NC Accepting Medicare

6 Physical Medicine & Rehabilitation doctors found. Showing 1 - 6

Christine Baytion Reinke, M.D. Physical Medicine & Rehabilitation Medicare: Not Enrolled in Medicare Practice Location: 102 Raphael Dr, Cary, NC 27511 Phone: 919-233-4811

Dr. Scott Steven Sanitate, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1120 Se Cary Pkwy Ste 100, Cary, NC 27518 Phone: 919-467-4992    Fax: 919-481-9607

Dr. Christopher Lin, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1110 Se Cary Pkwy, Cary, NC 27518 Phone: 919-297-0000

Christopher J Godbout, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 400 Keisler Dr, Cary, NC 27511 Phone: 919-781-9950    Fax: 919-783-9950

Dr. Nicole P Bullock, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 1120 Se Cary Pkwy, Suite 100, Cary, NC 27518 Phone: 919-467-4992    Fax: 919-232-5328

Dr. Emily Ann Fonke-fritz, PT, DPT Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 570 New Waverly Pl Ste 120, Cary, NC 27518 Phone: 919-803-3398

News Archive

Alverix receives FDA 510(k) clearance for new BD Veritor System kit

Alverix, Inc., a world leader in the design and manufacture of next-generation platforms for diagnostic Point-of-Care (POC) testing, today announced that BD Diagnostics, a segment of Becton Dickinson and Company, a leading global medical technology company, received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for nasopharyngeal wash, aspirate and swab in transport media specimens on the BD VeritorTM System for Rapid Detection of respiratory syncytial virus (RSV).

ImmunoCellular expands ICT-107 Phase II clinical trial for glioblastoma multiforme

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced the expansion of sites for its Phase II clinical trial of ICT-107. ICT-107 is the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme (GBM).

Men with cardiovascular risk factors more likely to develop peripheral artery disease

Among nearly 45,000 men who were followed up for more than two decades, those with the risk factors of smoking, hypertension, high cholesterol, and type 2 diabetes had an associated greater risk of developing PAD, according to a study in the October 24/31 issue of JAMA.

Online education enhances administration of blood clot-preventing medications

Results of a yearlong study funded by the Patient-Centered Outcomes Research Institute (PCORI) with more than 900 nurses at The Johns Hopkins Hospital suggest that well-designed online education can decrease the rate of nonadministration of prescribed and necessary doses of blood thinners to prevent potentially lethal blood clots in hospitalized patients.

Hand-eye coordination found to be dramatically more sensitive to alcohol

In previous studies, eye movements and vision were only affected at blood alcohol concentrations (BACs) approaching the legal limit for driving (0.08% BAC), in England, Wales and Northern Ireland.

Read more Medical News

› Verified 4 days ago